Retatrutide: Why the “Triple Agonist” Peptide Has Become the Most Watched Compound in Metabolic Research

Few research compounds have moved from obscurity to headline status as quickly as retatrutide. Developed by Eli Lilly under the code name LY3437943, the peptide has gone from early-stage trials to a full Phase 3 programme in just a few years, and it is now one of the most discussed molecules in metabolic science. For laboratories in the UK and across Europe, it has also become one of the most requested compounds for in-vitro and pre-clinical work.

What makes retatrutide different

Most of the incretin-based compounds that have dominated the conversation over the last decade act on one or two hormone receptors. Semaglutide targets the GLP-1 receptor alone. Tirzepatide added a second target, the GIP receptor. Retatrutide goes a step further by acting on three receptors at once: GLP-1, GIP and the glucagon receptor.

That third target is what has caught researchers’ attention. Glucagon signalling is associated with energy expenditure and the way the liver handles fat, so a single molecule that combines it with GLP-1 and GIP activity opens up questions that earlier compounds could not answer. This is why retatrutide is often described as a “triple agonist” or “triple G” peptide.

What the published trials have shown

The first major data set came from a Phase 2 trial published in the New England Journal of Medicine in 2023. Adults with obesity who received the highest dose tested lost an average of around 24% of their body weight over 48 weeks, a figure that was well above what had been reported for single-agonist compounds over a similar period.

Since then, Lilly has run a large Phase 3 programme known as TRIUMPH, covering obesity, type 2 diabetes, knee osteoarthritis and sleep apnoea. Early Phase 3 readouts have pointed in the same direction as the Phase 2 data, with substantial reductions in body weight alongside improvements in markers such as blood sugar, blood pressure and liver fat. Researchers are also watching closely for results on body composition, cardiovascular outcomes and tolerability as more of the programme reports.

It is worth stressing that retatrutide is still an investigational compound. It is not approved as a medicine in the UK, and outside of regulated clinical trials it is supplied strictly for laboratory research.

Why UK laboratories are paying attention

The interest in retatrutide is not only about headline weight-loss figures. Because it acts on three pathways, it gives researchers a useful tool for comparing how each receptor contributes to metabolic outcomes. Studies can look at receptor binding, cell signalling, fat metabolism in liver cell models, and how triple agonism compares with the dual and single agonists already on the market.

That demand has created a fast-growing supply market, and with it a familiar problem: quality varies enormously between suppliers. For research results to mean anything, the compound in the vial has to be what the label says it is, at the purity the label claims.

This is where independent testing matters. Reputable UK suppliers now publish third-party certificates of analysis from labs such as Janoshik, showing identity, purity and the actual amount of peptide in each vial. Suppliers such as Revial Labs retatrutide publish these results openly, stock the compound in the UK, and dispatch the same day, which matters for a peptide that should be kept cool and handled carefully.

What researchers should check before buying

• A recent, batch-matched certificate of analysis from an independent lab, not just an in-house claim.
• Purity of 98% or above, with the measured peptide content stated.
• UK stock and tracked, fast delivery, to keep the lyophilised powder in good condition.
• Clear labelling that the product is for laboratory research use only.

For a fuller overview of the compound, how it compares with tirzepatide and semaglutide, and what to look for in a UK supplier, the Retatrutide UK research guide is a useful starting point.

The bottom line

Retatrutide is likely to stay at the centre of metabolic research for years to come. As the remaining Phase 3 data arrives, the scientific picture will become clearer. In the meantime, the quality of the research being done in labs depends heavily on the quality of the compound being used, so independent testing and transparent suppliers are more important than ever.

This article is for information only. Retatrutide is an investigational compound and is supplied for laboratory research use only. It is not for human consumption.